Zennovation in sedation – the next generation of alpha-2 agonists’

Loading

Zennovation in sedation – the next generation of alpha-2 agonists’

17 Nov 2022
Gallery Suite 17
Zennovation in sedation – the next generation of alpha-2 agonists’

The presentation will provide a review of canine sedation, particularly the physiology of alpha-2 receptors and the pharmacology of alpha-2 adrenoreceptor agonists and their reversal. It will also introduce the unique new alpha-2 combination product, Zenalpha, containing the alpha-2 agonist medetomidine and the peripherally selective alpha-2 antagonist vatinoxan. Attendees will learn about the innovative mechanism of action of Zenalpha and how this provides unique benefits, including reduced cardiovascular side effects during sedation.

  • The physiology of alpha-2 receptors and that the location of the receptor influences its effect
  • The basic pharmacology of alpha-2 agonists and antagonists
  • How Zenalpha works, how to use it, what benefits it can bring, to canine patients and the team
Speakers
Matt Gurney, Clinical Director - Anderson Moores

Sponsors & Partners

Education Partners

  • RVC
  • BVA

Platinum Sponsors

  • Elanco
  • Hills
  • humm
  • Idexx
  • IVC
  • Vets4Pets
  • Virbac
  • Zoetis

Gold Sponsor

  • Pioneer

Silver Sponsors

  • Medivet
  • MWI
  • GreenCross
  • iM3
  • Petsapp
  • Lintbells

Wet Lab Partner

  • Central CPD

Media Partners

  • Vet Record
  • Vet Times
  • InPractice
  • Vet Nurse Times
  • VetFile
  • Vettimes.co.uk
  • Vet Times Jobs
  • VBJ
  • VetSurgeon

BE THE LEADER OF YOUR PACK

Be the first to hear the latest news, programme updates and exclusive industry releases.